STOCKHOLM – April 7, 2025. Umecrine Cognition today announces that the company will attend the high-level meeting International PBC Summit 2025 on April 8-11. The summit is organized by the…
STOCKHOLM – April 1, 2025. Umecrine Cognition today announces the appointment of Dr. Viktor Drvota as new Chief Executive Officer. He succeeds Anders Karlsson, who has served in the position since…
STOCKHOLM – April 1, 2025. Umecrine Cognition today announces that the company will attend the 19th International Conference on Alzheimer’s and Parkinson’s Diseases 2025 in Vienna,…
STOCKHOLM – March 18, 2025. Umecrine Cognition today announces that its Phase 1b/2a study of golexanolone has been delayed due to technical issues with the production of capsules used in the study….
STOCKHOLM – March 19, 2025. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Milan, Italy. The meeting takes place March 17–19th and is expected to gather…
STOCKHOLM – January 13, 2024. Umecrine Cognition today announced that the company will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, USA, on January 13–16, 2025….
STOCKHOLM – December 19, 2024. Umecrine Cognition today announced that the company has raised SEK 23,8 million through a convertible loan with attached share options directed to a consortium of…
STOCKHOLM – November 18, 2024. Umecrine Cognition today announces that the company will present late-breaking data from a recent interim analysis of the first part of its ongoing Phase 1b/2a…
STOCKHOLM – October [17], 2024. Umecrine Cognition today announces that the company will attend the 10th Edition of the International Conference on Neurology and Brain Disorders (INBC 2024) to…
STOCKHOLM – July 10, 2024. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 28,3 million according to plan to continue the development of its…